背景:难治性痉挛症状的治疗对于临床医生来说仍然是一项具有挑战性的任务。ITB疗法已成为治疗这种疾病的有希望的选择。这项研究评估了ITB治疗在治疗难治性痉挛症状中的有效性。
方法:对34例有难治性痉挛症状的患者进行回顾性分析,这些患者在一家机构接受了ITB治疗。病人的人口统计学,临床特征,并记录剂量。主要结果指标是疼痛的减轻,改善流动性,痉挛频率降低,缓解痉挛。
结果:ITB治疗成功地减轻了疼痛,改善流动性,痉挛频率降低,缓解痉挛.平均每日给药剂量为245μg(范围:88-510μg,SD:104)。然而,据观察,ITB治疗的合适剂量是患者特异性和时间敏感性的.此外,当剂量不正确时观察到副作用.
结论:鞘内注射巴氯芬治疗是治疗难治性痉挛症状的有效和安全的选择。然而,适当的剂量应个体化,并密切监测,以避免副作用。这项研究强调了仔细考虑ITB治疗对每位患者的潜在风险和益处的重要性。
BACKGROUND: Management of refractory spasticity symptoms remains a challenging task for clinicians. Intrathecal baclofen (ITB) therapy has emerged as a promising option for treating this condition. This study evaluates the effectiveness of ITB therapy in managing refractory spasticity symptoms.
METHODS: A retrospective chart review was conducted on 34 patients with refractory spasticity symptoms who underwent ITB therapy at a single institution. The patients\' demographics, clinical characteristics, and dosages were recorded. The primary outcome measures were the reduction in pain, improvement in mobility, decrease in spasm frequency, and alleviation of spasticity.
RESULTS: ITB therapy successfully reduced pain, improved mobility, decreased spasm frequency, and alleviated spasticity. The mean daily administered dose was 245 μg (range: 88-510 μg, standard deviation:104). However, it was observed that the appropriate dosage of ITB therapy was patient-specific and time-sensitive. Moreover, side effects were observed when an incorrect dose was administered.
CONCLUSIONS: ITB therapy is an effective and safe option for managing refractory spasticity symptoms. However, the appropriate dosage should be individualized and monitored closely to avoid side effects. This study highlights the importance of carefully considering the potential risks and benefits of ITB therapy for each patient.